Ablexis' AlivaMab Mouse平台将33名人体抗体药物候选者推入临床试验,比上一年增加80%,其中两个在关键的第三阶段试验中。 Ablexis' AlivaMab Mouse platform advanced 33 human antibody drug candidates into clinical trials, an 80% increase year-over-year, with two in pivotal Phase 3 trials.

Ablexis报告说,AlivaMab鼠标平台的33名人体抗体药物候选者已进入临床开发阶段,逐年增加80%,其中2人目前处于关键的第三阶段试验阶段。 Ablexis reports 33 human antibody drug candidates from its AlivaMab Mouse platform have entered clinical development, an 80% year-over-year increase, with two now in pivotal Phase 3 trials. 该平台是为有效发现人体抗体而设计的,已被合作伙伴验证,目的是提高打击率、多样性和附着性覆盖率。 The platform, designed for efficient human antibody discovery, has been validated by partners for improving hit rates, diversity, and epitope coverage. 该公司根据里程碑和免特许使用费条件向合作伙伴提供技术和综合发现服务。 The company offers the technology and integrated discovery services to partners under milestone- and royalty-free terms.